Brokers Issue Forecasts for SNTI Q3 Earnings

Senti Biosciences, Inc. (NASDAQ:SNTI) – Research analysts at HC Wainwright issued their Q3 2026 EPS estimates for Senti Biosciences in a research note issued to investors on Tuesday, September 15th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.38) per share for the quarter. HC Wainwright also issued estimates for Senti Biosciences’ Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.53) EPS, FY2027 earnings at ($0.94) EPS, FY2028 earnings at ($0.72) EPS, FY2029 earnings at ($0.48) EPS and FY2030 earnings at ($0.20) EPS.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.08). The business had revenue of $0.02 million for the quarter.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Senti Biosciences Stock Up 1.5%

Shares of SNTI opened at $0.34 on Friday. The firm has a market cap of $10.68 million, a price-to-earnings ratio of -0.19 and a beta of 2.12. The business’s 50 day moving average is $0.37 and its two-hundred day moving average is $0.75. Senti Biosciences has a 52-week low of $0.29 and a 52-week high of $2.88.

Senti Biosciences Company Profile

Senti Biosciences, Inc is a biotechnology company focused on developing programmable cell and gene therapies. Its technology platform uses synthetic biology and genetic circuits to engineer cells that can recognize disease-related signals and activate therapeutic functions in a controlled manner.

The company’s development programs have included engineered immune-cell therapies, including CAR-NK and other cell-based treatments designed for oncology applications. Senti Bio has also developed gene-circuit technologies intended to improve the targeting, safety and activity of therapeutic cells, with potential applications in cancer and other serious diseases.

Founded in 2016 and headquartered in San Francisco, California, Senti Bio has worked with biotechnology and pharmaceutical partners to advance its platform and therapeutic candidates.